Turning disorder druggable
LATEST NEWS
INTRAMETICS™ Platform revolutionizes drug discovery, empowering design against Intrinsically Disordered Proteins (IDPs)
IDP Pharma is a clinical stage company harnessing its proprietary INTRAMETICS™ platform to tackle long-quested disease drivers: intrinsically disordered proteins (IDPs). Our molecules activate the degradation of IDPs through the intrinsic cells machinery, representing breakthrough treatments for incurable diseases/cancers.
Team
Santiago Esteban
Co-founder & CEO
Santiago is co-founder and current CEO of IDP Pharma. He earned his Ph.D in chemistry from the Institute of Molecular Science in Spain and gained valuable expertise through his work at esteemed international institutions such as KIT, Groningen Institute of Biotechnology, and IRB. Since the inception of IDP Pharma, he played a pivotal role in steering the company towards success, focusing on strategic growth and business development initiatives. Santiago is an expert in therapeutic targets that pose challenges for modulation, particularly Intrinsically Disordered Proteins (IDPs). Under his leadership, IDP Pharma continues to thrive, committed to addressing unmet medical needs and advancing therapeutic solutions for complex diseases.
Santiago Esteban, PhD
Co-founder & CEO
Laura Nevola
Co-founder & CSO/COO
Laura is co-founder of IDP Pharma and currently serves as the Chief Scientific Officer (CSO) and Chief Operating Officer (COO). She earned her degree in medicinal chemistry and Ph.D. in Pharmaceutical Science from the University of Rome “Sapienza” (Italy). Following her tenure at the laboratory of Prof. Dr. Hamilton at Yale University (USA), she transitioned to the Institute for Research in Biomedicine (IRB Barcelona). With a comprehensive background in medicinal chemistry and biotechnology, she specializes in peptidomimetics. Over the last ten years she has designed several de novo drugs and led multiple drug discovery projects and is member of the Advisory Board of the Peptide Drug Hunting Consortium. Additionally, she holds a Master's in Executive Education – Marketing Management (IMD-Lousanne). In 2019 Dr. Nevola has been awarded with the European Award for Women Entrepreneur thanks to the achievements of IDP Pharma.
Laura Nevola, PhD
Co-founder & CSO/COO
Tim Hammond
Chief Development Officer
Tim is Doctor cum laude in Toxicology and Pharmacokinetics from the University of Birmingham, former president of the British Society of Toxicology and honorary professor at the University of Liverpool, with over 35 years of experience in new drug development, notably as Vice President of Safety Assessment at Astrazeneca UK, where he has been responsible for the non-clinical safety development of the entire oncology portfolio, including the registration of Irressa and Olaparib.
Tim Hammond, PhD
Chief Development Officer
Laura Orozco
Head of Finance
Mrs Orozco is a senior financial director that held directive positions at several companies. During her tenure at Vantum Corporate, a firm focused on biotech startups acquired by Deloitte in 2020, she honed her expertise in the biotechnology sector.
Laura Orozco
Head of Finance
Fabiana Subrizi
Head of R&D
As the Head of Research and Development (R&D), Fabiana boasts extensive international experience, specializing in leading multidisciplinary projects at prestigious institutions such as University College London (UCL) and top-tier companies. With a dynamic background as a Chemist and a Ph.D. in Pharmaceutical Sciences (joint program at the University of Rome and the University of Barcelona), she has a combination of scientific expertise and project management competencies, bringing over 15 years of invaluable expertise to our team.
Fabiana Subrizi, PhD
Head of R&D
David Molina
Clinical Operations Manager
With a focus on oncology clinical trial coordination and execution, David has mastered his skills while working with international pharmaceutical companies and clinical Contract Research Organizations (CROs). He obtained a Ph.D. in Biochemistry, Molecular Biology, and Biomedicine, and his academic background serves as a strong foundation for his role in the clinical research arena. His dedication to ensuring the smooth coordination and successful execution of clinical trials has made him a valuable asset in the field.
David Molina, PhD
Clinical Operations Manager
Maria Fernanda Montenegro
Head of Biology
As the Head of Biology, Fernanda brings a wealth of expertise in cancer biology to our team. Her educational journey includes studying biology and biochemistry, culminating in a Bachelor's and Master's degree from the University of Vigo, followed by a Ph.D. in Biology from the University of Murcia. With a deep-rooted passion for unraveling the complexities of cancer, her specialized knowledge and scientific experience drive innovation and excellence in our biological research programs.
Maria Fernanda Montenegro, PhD
Head of Biology
Scientific Advisory Board
Tomi Sawyer
PhD (Chairman; President at Maestro Therapeutics)
Tomi is a distinguished academic and renowned scientist in the biotechnology and pharmaceutical fields. With leadership roles at Merck and as former Chief Scientific Officer at Aileron, he achieved a remarkable milestone by pioneering the introduction of a stapled peptide into clinical trials. His groundbreaking work has resulted in the successful development and commercialization of two market-leading drugs, Scenesse® and Iclusig®. With around 600 scientific publications, patents, and presentations, he continues to drive innovation. Additionally, he holds Adjunct Professorships at esteemed institutions including the University of Massachusetts and Northeastern University Center for Drug Discovery
PhD (President at Maestro Therapeutics)
Dean W. Felsher
M.D. Ph.D. (Stanford University)
Dr. Felsher is internationally regarded for his basic and translational research in cancer. He is a recipient of the National Cancer Institute Outstanding Investigator Award. He is the founding Director of Translational Research and Applied Medicine (TRAM), Advanced Residency Training (ARTS), Cancer Nanotechnology Training (CTNT) and the Stanford KL2 Mentor Program. He has pioneered the utilization of the Tet System to study lymphoma, as well as liver, kidney, bone and lung cancer. He has developed novel nanotechnologies, proteomic methods, molecular imaging agents and molecular therapeutics. Dr. Felsher’s work has established scientific concepts of the “reversibility of cancer,” “oncogene addiction,” and “tumor maintenance.” Dr. Felsher has been elected to the American Society of Clinical Investigation and Association of American Physicians.
M.D. Ph.D. (Stanford University)
Jane E. Johnson
PhD (UT Southwestern Medical Center)
Jane is recognized as a distinguished academic for her groundbreaking research in transcriptional mechanisms governing nervous system development and neuroendocrine cancers. Her pioneering work unveiled ASCL1 (formerly known as MASH1), a critical transcription factor involved in neural development and neuroendocrine cancer progression. Dr. Johnson currently occupies the prestigious Shirley and William S. McIntyre Distinguished Chair in Neuroscience.
PhD. (UT Southwestern Medical Center; Shirley and William S. McIntyre Distinguished Chair in Neuroscience)
Sir Peter John Ratcliffe (Nobel Laureate)
FRS, FMedSci (University of Oxford, Francis Crick Institute)
Peter J. Ratcliffe FRS is a seasoned physician-scientist with over three decades of expertise in studying cellular reactions to low oxygen (hypoxia). His laboratory has been instrumental in uncovering mechanisms that detect and adapt to oxygen levels, earning him numerous accolades, notably the 2019 Nobel Prize in Physiology or Medicine. Peter serves as a Distinguished Scholar at the Ludwig Institute for Cancer Research, heads the Target Discovery Institute at the University of Oxford, and holds the position of Clinical Research Director at the Francis Crick Institute in London.
FRS, FMedSci (University of Oxford; Francis Crick Institute)
Andrew Spencer
MBBS, FRACP, FRCPA, DM (Alfred Health-Monash University)
Andrew Spencer is a clinician-scientist and an internationally recognized expert in multiple myeloma with a focus on disease biomarkers, developmental therapeutics and early phase drug trials. He has had a longstanding involvement with pharma engaged in pre-clinical and early clinical phase development of small molecules and immune-therapeutics. He established and leads large-scale real-world evidence-based myeloma research via the Australia & New Zealand and the APAC Myeloma & Related Diseases Registries.
MBBS, FRACP, FRCPA, DM (Alfred Health-Monash University)
Breaking New Ground: IDP-121 Clinical Trial for MYC-Driven Hematological Cancers
IDP Pharma is currently conducting a clinical trial in individuals with MYC-driven hematological cancers. This phase I/Ib clinical study (CASSANDRA) is underway at renowned hospital centers across Spain and aims to evaluate the safety, tolerability, and anti-tumor activity of IDP-121 in selected cancer patients. Details about the IDP-121 clinical trial can be found at clinicaltrials.gov under identifier: NCT05908409.
